The peripheral blood immune cell profile in a teriflunomide-treated multiple sclerosis patient with COVID-19 pneumonia,Journal of Neuroimmunology

当前位置： X-MOL 学术 › J. Neuroimmunol. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

The peripheral blood immune cell profile in a teriflunomide-treated multiple sclerosis patient with COVID-19 pneumonia
Journal of Neuroimmunology ( IF 2.9 ) Pub Date : 2020-09-01 , DOI: 10.1016/j.jneuroim.2020.577323
Maria Rosa Ciardi ₁ , Maria Antonella Zingaropoli ₁ , Patrizia Pasculli ₁ , Valentina Perri ₁ , Matteo Tartaglia ₂ , Serena Valeri ₁ , Gianluca Russo ₁ , Antonella Conte ₃ , Claudio Maria Mastroianni ₁

Affiliation

Abstract A teriflunomide-treated multiple sclerosis patient with COVID-19 pneumonia was hospitalized and recovered in 15 days. The immunophenotyping analysis of peripheral blood cells was performed in two time points: the first was 1 month before (pre-infection) while the second was during COVID-19 pneumonia (infection). At the infection time point, no differences in the percentages of immune activation and immunesenescence of CD4+ and CD8+ T-cells were observed compared to the pre-infection time point. Our evaluation seems to confirm that teriflunomide control T-cells immune activation and immunosenescence suggesting that teriflunomide should not be discontinued in MS patients with an active COVID-19 pneumonia.

中文翻译：

接受特立氟胺治疗的多发性硬化症 COVID-19 肺炎患者的外周血免疫细胞谱

摘要一名接受特立氟胺治疗的多发性硬化症 COVID-19 肺炎患者住院，15 天内康复。外周血细胞的免疫表型分析在两个时间点进行：第一个时间点是感染前1个月，第二个时间点是COVID-19肺炎期间（感染期间）。在感染时间点，与感染前时间点相比，CD4+和CD8+T细胞的免疫激活和免疫衰老百分比没有观察到差异。我们的评估似乎证实了特立氟胺控制 T 细胞免疫激活和免疫衰老，表明患有活动性 COVID-19 肺炎的多发性硬化症患者不应停用特立氟胺。

更新日期：2020-09-01

点击分享查看原文

点击收藏

公开下载

阅读更多本刊最新论文本刊介绍/投稿指南11